Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ARS Pharmaceuticals, Inc. - Common Stock
(NQ:
SPRY
)
4.290
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ARS Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
March 05, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
March 03, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
February 20, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 13, 2024
↗
November 13, 2024
Via
Benzinga
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings
↗
November 12, 2024
Via
Benzinga
Where ARS Pharmaceuticals Stands With Analysts
↗
October 08, 2024
Via
Benzinga
Analyst Ratings For ARS Pharmaceuticals
↗
September 09, 2024
Via
Benzinga
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
February 18, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
February 05, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
January 21, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
↗
January 17, 2025
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Via
Investor's Business Daily
Topics
Economy
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
↗
January 13, 2025
Some companies saw their shares skyrocket on preliminary reports, but others took hits.
Via
Investor's Business Daily
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
January 13, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
January 06, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
December 19, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
December 12, 2024
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
December 04, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
↗
November 11, 2024
Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it.
Via
Investor's Business Daily
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
↗
November 11, 2024
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.
Via
Benzinga
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
November 11, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
November 06, 2024
Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ET
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
October 24, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
September 23, 2024
Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
September 09, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
September 04, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
August 26, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
↗
August 23, 2024
Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
